anaplastic large cell lymphoma (Cancer)
Information
- Disease name
- anaplastic large cell lymphoma
- Disease ID
- DOID:0050744
- Description
- "A non-Hodgkin lymphoma involving aberrant T-cells." [url:http\://en.wikipedia.org/wiki/Anaplastic_large-cell_lymphoma#Epidemiology]
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT04526834 | Active, not recruiting | Phase 1 | Phase 1 Study of Autologous CD30.CAR-T in Relapsed or Refractory CD30 Positive Non-Hodgkin Lymphoma | September 8, 2021 | March 2036 |
| NCT01793233 | Active, not recruiting | Blood Sample Markers of Reproductive Hormones in Assessing Ovarian Reserve in Younger Patients With Newly Diagnosed Lymphomas | June 17, 2013 | December 31, 2024 | |
| NCT02232516 | Active, not recruiting | Phase 2 | Romidepsin and Lenalidomide in Treating Patients With Previously Untreated Peripheral T-Cell Lymphoma | June 11, 2015 | August 2024 |
| NCT03598998 | Active, not recruiting | Phase 1/Phase 2 | Pembrolizumab and Pralatrexate in Treating Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas | February 4, 2019 | June 29, 2024 |
| NCT00006251 | Completed | Phase 1/Phase 2 | Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine, Mycophenolate Mofetil, Donor Lymphocyte Infusion in Treating Patients With Hematopoietic Cancer | May 2000 | |
| NCT00014235 | Completed | N/A | Fludarabine Phosphate and Total-Body Radiation Followed by Donor Peripheral Blood Stem Cell Transplant and Immunosuppression in Treating Patients With Hematologic Malignancies | December 2000 | |
| NCT00016094 | Completed | Phase 2 | S0108 Bevacizumab in Treating Patients With Non-Hodgkin's Lymphoma | April 2001 | September 2008 |
| NCT00025415 | Completed | Phase 1 | Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction | August 2001 | |
| NCT00040846 | Completed | Phase 2 | Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation in Treating Patients With Hematological Malignancies | November 2001 | December 2009 |
| NCT00049504 | Completed | Phase 2 | Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancer | January 2002 | February 2014 |
| NCT00058019 | Completed | Phase 2 | Ixabepilone in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma | February 2003 | August 2010 |
| NCT00072514 | Completed | Phase 2 | Gemcitabine Hydrochloride, Carboplatin, Dexamethasone, and Rituximab in Treating Patients With Previously Treated Lymphoid Malignancies | August 2003 | November 2013 |
| NCT00073918 | Completed | Phase 2 | Iodine I 131 Tositumomab, Etoposide and Cyclophosphamide Followed by Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma | February 1999 | October 2, 2011 |
| NCT00077155 | Completed | Phase 1 | Cilengitide (EMD 121974) in Treating Patients With Advanced Solid Tumors or Lymphoma | December 2003 | |
| NCT00078858 | Completed | Phase 1/Phase 2 | Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant | September 2003 | |
| NCT00082888 | Completed | Phase 2 | Tipifarnib in Treating Patients With Relapsed or Refractory Lymphoma | March 24, 2004 | July 5, 2017 |
| NCT00089011 | Completed | Phase 2 | Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant for Hematologic Cancer | April 2004 | July 2018 |
| NCT00089271 | Completed | Phase 1 | 17-DMAG in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphomas | July 2004 | |
| NCT00098891 | Completed | Phase 1 | MS-275 and Isotretinoin in Treating Patients With Metastatic or Advanced Solid Tumors or Lymphomas | October 2004 | |
| NCT00112593 | Completed | N/A | Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer | November 1999 | |
| NCT00117988 | Completed | Phase 2 | 17-AAG in Treating Patients With Relapsed or Refractory Anaplastic Large Cell Lymphoma, Mantle Cell Lymphoma, or Hodgkin's Lymphoma | February 2005 | April 2010 |
| NCT00118352 | Completed | Phase 2 | Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer | March 2005 | May 26, 2015 |
| NCT00131937 | Completed | Phase 2 | Sorafenib Tosylate in Treating Patients With Recurrent Aggressive Non-Hodgkin's Lymphoma | October 2005 | August 2012 |
| NCT00278382 | Completed | Phase 2 | Sorafenib in Treating Patients With Recurrent Non-Hodgkin's Lymphoma | October 2005 | |
| NCT00293345 | Completed | Phase 1 | 3-AP and Gemcitabine in Treating Patients With Advanced Solid Tumors or Lymphoma | June 2006 | |
| NCT00343798 | Completed | Phase 1 | A Pilot Study to Evaluate the Co-Infusion of Ex Vivo Expanded Cord Blood Cells With an Unmanipulated Cord Blood Unit in Patients Undergoing Cord Blood Transplant for Hematologic Malignancies | April 2006 | |
| NCT00348985 | Completed | Phase 1 | PXD101 and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas | March 2006 | |
| NCT03493451 | Completed | Phase 2 | Study of BGB-A317 in Participants With Relapsed or Refractory Mature T- and NK-cell Neoplasms | April 13, 2018 | April 21, 2021 |
| NCT00003970 | Completed | Phase 1 | Genetic Testing Plus Irinotecan in Treating Patients With Solid Tumors or Lymphoma | January 1999 | |
| NCT00004241 | Completed | Phase 1 | 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Advanced Epithelial Cancer, Malignant Lymphoma, or Sarcoma | October 1999 | |
| NCT00005080 | Completed | Phase 2 | 506U78 in Treating Patients With Lymphoma | May 2000 | |
| NCT01129180 | Completed | Phase 1 | Bortezomib and Azacitidine in Treating Patients With Relapsed or Refractory T-Cell Lymphoma | May 2010 | December 2012 |
| NCT01129193 | Completed | Phase 1 | AR-42 in Treating Patients With Advanced or Relapsed Multiple Myeloma, Chronic Lymphocytic Leukemia, or Lymphoma | May 4, 2010 | January 7, 2017 |
| NCT01158274 | Completed | Phase 1 | RO4929097 and Capecitabine in Treating Patients With Refractory Solid Tumors | June 2010 | |
| NCT01177371 | Completed | Phase 2 | High-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patients With Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, or Recurrent Hodgkin or Non-Hodgkin Lymphoma | March 1988 | February 2010 |
| NCT01199562 | Completed | Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant | December 2010 | December 2013 | |
| NCT01254578 | Completed | Phase 1 | Lenalidomide After Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancers | November 24, 2010 | November 9, 2012 |
| NCT01258998 | Completed | Phase 2 | Study of Akt Inhibitor MK2206 in Patients With Relapsed Lymphoma | December 2010 | August 2015 |
| NCT01261247 | Completed | Phase 2 | Panobinostat in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma | January 17, 2011 | December 2, 2019 |
| NCT01273766 | Completed | Phase 2 | Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies | January 2011 | December 2014 |
| NCT01326702 | Completed | Phase 1/Phase 2 | Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors | July 2011 | April 2015 |
| NCT01336920 | Completed | Phase 1 | Carfilzomib in Treating Patients With Relapsed or Refractory T-Cell Lymphoma | June 21, 2011 | March 1, 2018 |
| NCT01336933 | Completed | Phase 2 | Combination Chemotherapy and Pralatrexate as First-Line Therapy in Treating Patients With Non-Hodgkin Lymphoma | July 6, 2011 | December 28, 2016 |
| NCT01427881 | Completed | Phase 2 | Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies | September 2011 | July 2015 |
| NCT01466881 | Completed | Phase 2 | Alisertib in Treating Patients With Relapsed or Refractory Peripheral T-Cell Non-Hodgkin Lymphoma | October 2011 | March 2015 |
| NCT01529827 | Completed | Phase 2 | Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies | February 28, 2012 | August 29, 2019 |
| NCT01567709 | Completed | Phase 1 | Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell Lymphoma | April 16, 2012 | March 29, 2018 |
| NCT01588015 | Completed | Phase 1 | Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant | October 29, 2012 | February 2, 2024 |
| NCT01657331 | Completed | Phase 1/Phase 2 | Brentuximab Vedotin and Bendamustine for the Treatment of Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma (ALCL) | July 2012 | April 2020 |
| NCT01658319 | Completed | Phase 1 | Methoxyamine and Fludarabine Phosphate in Treating Patients With Relapsed or Refractory Hematologic Malignancies | May 2011 | May 2015 |
| NCT01686165 | Completed | Phase 2 | Belinostat and Yttrium Y 90 Ibritumomab Tiuxetan in Patients W/Relapsed Aggressive B-Cell NHL | August 31, 2012 | November 9, 2017 |
| NCT01748721 | Completed | Phase 1 | MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma | November 2013 | May 2015 |
| NCT01839916 | Completed | Phase 2 | Donor T Cells After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies | April 4, 2013 | August 2018 |
| NCT01943682 | Completed | Phase 1 | Safety Study of CPX-351 in Children With Relapsed Leukemia or Lymphoma | September 2013 | April 2019 |
| NCT01959477 | Completed | Early Phase 1 | Dose Monitoring of Busulfan and Combination Chemotherapy in Hodgkin or Non-Hodgkin Lymphoma Undergoing Stem Cell Transplant | March 2014 | April 2015 |
| NCT02168140 | Completed | Phase 1 | CPI-613 and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma | September 2014 | September 15, 2022 |
| NCT02652715 | Completed | N/A | Salvia Hispanica Seed in Reducing Risk of Disease Recurrence in Patients With Non-Hodgkin Lymphoma | January 19, 2016 | November 12, 2019 |
| NCT03397953 | Completed | Phase 2 | Vinorelbine for Recurrent ACLC | November 2016 | July 2022 |
| NCT00003196 | Completed | N/A | Low-Dose Total Body Irradiation and Donor Peripheral Blood Stem Cell Transplant Followed by Donor Lymphocyte Infusion in Treating Patients With Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma | September 1997 | April 2002 |
| NCT03534180 | Completed | Phase 2 | Venetoclax and Romidepsin in Treating Patients With Recurrent or Refractory Mature T-Cell Lymphoma | August 21, 2018 | July 26, 2023 |
| NCT03905135 | Completed | Phase 1 | Interleukin-15 (IL-5) in Combination With Avelumab (Bavencio) in Relapsed/Refractory Mature T-cell Malignancies | June 7, 2019 | May 17, 2022 |
| NCT00458731 | Completed | Phase 1 | Bevacizumab and Cediranib Maleate in Treating Patients With Metastatic or Unresectable Solid Tumor, Lymphoma, Intracranial Glioblastoma, Gliosarcoma or Anaplastic Astrocytoma | May 2007 | |
| NCT00499811 | Completed | Phase 1 | Vorinostat in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma and Liver Dysfunction | June 2007 | |
| NCT00601718 | Completed | Phase 1/Phase 2 | Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Lymphoma or Previously Untreated T-Cell Non-Hodgkin Lymphoma or Mantle Cell Lymphoma | December 2007 | |
| NCT00606645 | Completed | Phase 1 | Safety Study of XmAb®2513 to Treat Hodgkin Lymphoma or Anaplastic Large Cell Lymphoma | December 2007 | April 2010 |
| NCT00608361 | Completed | Phase 1 | Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surgery | October 2008 | August 2014 |
| NCT00697346 | Completed | Phase 1 | Study of MLN8237 in Participants With Advanced Hematological Malignancies | July 11, 2008 | October 19, 2016 |
| NCT00720135 | Completed | Phase 1 | Fusion Protein Cytokine Therapy After Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma | January 2008 | July 2014 |
| NCT00769288 | Completed | Phase 1 | FAU in Treating Patients With Advanced Solid Tumors or Lymphoma | July 2009 | |
| NCT00856388 | Completed | N/A | Fludarabine Phosphate, Melphalan, Total-Body Irradiation, Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Bone Marrow Failure Disorders | January 14, 2009 | March 13, 2019 |
| NCT00890747 | Completed | Phase 1 | Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy | August 2009 | |
| NCT00918333 | Completed | Phase 1/Phase 2 | Panobinostat and Everolimus in Treating Patients With Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or Hodgkin Lymphoma | June 2009 | July 16, 2019 |
| NCT01075321 | Completed | Phase 1/Phase 2 | Everolimus and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma | January 10, 2011 | February 13, 2020 |
| NCT01110135 | Completed | Phase 2 | Bendamustine Hydrochloride, Etoposide, Dexamethasone, and Filgrastim For Peripheral Blood Stem Cell Mobilization in Treating Patients With Refractory or Recurrent Lymphoma or Multiple Myeloma | August 2010 | |
| NCT05907447 | Not yet recruiting | A Retrospective Study on Extranodal Lymphoma or Lymphoma of Rare Pathological Types | July 1, 2023 | October 1, 2024 | |
| NCT01787409 | Recruiting | N/A | Cholecalciferol in Improving Survival in Patients With Newly Diagnosed Cancer With Vitamin D Insufficiency | March 6, 2013 | March 28, 2025 |
| NCT05770037 | Recruiting | Phase 2/Phase 3 | DETERMINE Trial Treatment Arm 01: Alectinib in Adult, Teenage/Young Adults (TYA) and Paediatric Patients With ALK Positive Cancers | December 18, 2023 | October 2029 |
| NCT03590574 | Recruiting | Phase 1/Phase 2 | Phase I/II Study Evaluating AUTO4 in Patients With TRBC1 Positive T Cell Lymphoma | August 30, 2018 | July 2025 |
| NCT03383965 | Recruiting | Phase 1 | CD30 Targeted CAR-T in Treating CD30-Expressing Lymphomas | March 1, 2017 | December 31, 2025 |
| NCT05290155 | Recruiting | Phase 1 | Anti-CD7 CAR-T Cell Therapy for Relapse and Refractory CD7 Positive T Cell Malignancies | May 4, 2022 | November 1, 2024 |
| NCT03443128 | Recruiting | Phase 2 | Vinorelbine for Recurrent ALCL-2017 | November 2016 | September 2025 |
| NCT05377827 | Recruiting | Phase 1 | Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic Malignancies | October 10, 2023 | April 30, 2026 |
| NCT04195633 | Recruiting | Phase 2 | Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies | January 25, 2021 | December 31, 2026 |
| NCT01769222 | Terminated | Phase 1 | Ipilimumab and Local Radiation for Selected Solid Tumors | February 2013 | June 2015 |
| NCT00354107 | Terminated | Phase 1/Phase 2 | Ifosfamide, Carboplatin, Etoposide, and SGN-30 in Treating Young Patients With Recurrent Anaplastic Large Cell Lymphoma | January 2007 | January 2010 |
| NCT00354185 | Terminated | Phase 1 | PXD101 and 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma | May 2006 | |
| NCT00365274 | Terminated | Phase 2 | SGN-30 and Combination Chemotherapy in Treating Patients With Newly Diagnosed Anaplastic Large Cell Lymphoma | August 2006 | May 2010 |
| NCT01408043 | Terminated | N/A | Etoposide, Filgrastim, and Plerixafor in Improving Stem Cell Mobilization in Treating Patients With Non-Hodgkin Lymphoma | October 2011 | May 2016 |
| NCT01419795 | Terminated | Phase 2 | Lenalidomide With or Without Rituximab in Treating Patients With Progressive or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Prolymphocytic Leukemia, or Non-Hodgkin Lymphoma Previously Treated With Donor Stem Cell Transplant | May 2012 | |
| NCT00704691 | Terminated | Early Phase 1 | Lenalidomide Therapy for Patients With Relapsed and/or Refractory, Peripheral T-Cell Lymphomas | June 2008 | December 2009 |
| NCT01678443 | Terminated | Phase 1 | Monoclonal Antibody Therapy Before Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoid Malignancies | September 1, 1999 | September 27, 2018 |
| NCT00103272 | Terminated | Phase 1 | 17-N-Allylamino-17-Demethoxygeldanamycin and Bortezomib in Treating Patients With Relapsed or Refractory Hematologic Cancer | April 2005 | |
| NCT01116154 | Terminated | Phase 1 | Vorinostat and Lenalidomide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma | May 2010 | August 2010 |
| NCT01805037 | Terminated | Phase 1/Phase 2 | Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas | March 5, 2013 | December 31, 2018 |
| NCT03947255 | Terminated | Phase 2 | A Study of Retreatment With Brentuximab Vedotin in Subjects With Classic Hodgkin Lymphoma or CD30-expressing Peripheral T Cell Lymphoma | October 28, 2019 | November 6, 2022 |
| NCT00096005 | Terminated | Phase 1 | Tanespimycin and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas | November 2004 | |
| NCT00112723 | Terminated | Phase 1/Phase 2 | Flavopiridol in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma | December 2005 | November 2015 |
| NCT02465528 | Terminated | Phase 2 | Ceritinib Rare Indications Study in ALK+ Tumors | May 6, 2016 | August 20, 2018 |
| NCT04008394 | Unknown status | Phase 1 | Anti-CD30 CAR-T Therapy in Patients With Refractory/Relapsed Lymphocyte Malignancies | July 3, 2019 | January 1, 2023 |
| NCT05208853 | Unknown status | Early Phase 1 | An Exploratory Clinical Study Evaluating the Safety and Efficacy of Anti CD30 CAR T Cells in Patients With CD30+ Relapsed/Refractory Lymphoma | February 10, 2022 | February 10, 2022 |
| NCT01769911 | Withdrawn | N/A | Genetically Modified Peripheral Blood Stem Cell Transplant in Treating Patients With HIV-Associated Non-Hodgkin or Hodgkin Lymphoma | February 2015 | |
| NCT01652014 | Withdrawn | Phase 2 | Single or Double Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Hematologic Malignancies | January 2014 | January 2017 |
| NCT00310128 | Withdrawn | Phase 2 | Combination Chemotherapy Followed by Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin's Lymphoma | February 2006 | |
| NCT03205891 | Withdrawn | Phase 1 | Study of Brentuximab Vedotin Plus TAK228 for Relapsed/Refractory Classical Hodgkin Lymphoma, Anaplastic Large Cell Lymphoma and Other CD30+Peripheral T-Cell Lymphomas | March 2018 | March 2021 |
- Disase is a (Disease Ontology)
- DOID:0060060
- Cross Reference ID (Disease Ontology)
- ICDO:9714/3
- Cross Reference ID (Disease Ontology)
- NCI:C3720
- OrphaNumber from OrphaNet (Orphanet)
- 98841